RNTX — Rein Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1420565 ·
Last close
$1.07
Market Cap
$91.53M
52W High
$2.10
52W Low
$0.95
ADV30
1,061,024
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,230,000 | -5,838,000 | 26,288,000 | 4,445,000 | 59,702,000 |
| Dec 2025 | 0 | — | -3,959,000 | -31,967,000 | 24,158,000 | 3,215,000 | 52,245,000 |
| Sep 2025 | 0 | — | -5,492,000 | -5,581,000 | 53,706,000 | 4,048,000 | 52,521,000 |
| Jun 2025 | 0 | — | -6,871,000 | -6,822,000 | 57,479,000 | 5,722,000 | 54,471,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,361,000
Investing CF
$0
Financing CF
$9,755,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.01
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-401,271,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-21,931,000
Pretax Income TTM
$-50,583,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -21,931,000 | -49,871,000 | 24,158,000 | 52,245,000 | — | -19,361,000 |
| Dec 2024 | 0 | -28,112,000 | -62,883,000 | 62,190,000 | 52,803,000 | — | -22,291,000 |
| Dec 2023 | 0 | -15,348,000 | -15,732,000 | 106,008,000 | 99,121,000 | — | -19,808,000 |
| Dec 2022 | 0 | -27,647,000 | -27,329,000 | 22,007,000 | 3,384,000 | — | -24,865,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANIX | Anixa Biosciences Inc | $91.53M | $2.73 | — |
| AARD | Aardvark Therapeutics, Inc. | $91.63M | $4.20 | — |
| IBIO | iBio, Inc. | $90.41M | $1.82 | — |
| PMN | ProMIS Neurosciences Inc. | $92.91M | $10.36 | — |
| FBIO | Fortress Biotech, Inc. | $89.36M | $2.69 | — |
News headlines (Yahoo Finance, 1h cache)
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
2026-05-18 12:00 · Yahoo
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
2026-05-01 00:00 · Yahoo
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
2026-04-29 12:00 · Yahoo
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
2026-03-03 13:00 · Yahoo
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
2026-01-20 13:00 · Yahoo
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
2025-11-06 12:30 · Yahoo
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
2025-11-03 12:30 · Yahoo
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
2025-10-09 11:30 · Yahoo
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
2025-09-17 11:30 · Yahoo
Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls
2025-08-19 13:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.